otenaproxesul otenaproxesul otenaproxesul is a analgesic and anti-inflammatory drug being developed by antibe therapeutics. an nsaid structurally derived from naproxen, in 2016 it received approval to commence phase ii clinical trials as a treatment for osteoarthritis after completing phase i clinical trials in 2015. in 2018, the drug completed trials for gastrointestinal safety, and in 2020 completed phase iib trials on efficacy of pain reduction. initial phase iii clinical trials in 2021 failed to meet the necessary criteria to advance to the next phase. otenaproxesulclinical dataother namesatb-352routes ofadministrationby mouthatc codenonelegal statuslegal status us: investigational new drug identifiers iupac name 4-carbamothioylphenyl (2s)-2-(6-methoxy-2-naphthyl)propanoate cas number1000700-29-7 ypubchem cid25065981chemspider32701263uniiv44gcu5p5ochemblchembl4211107chemical and physical dataformulac21h19no3smolar mass365.45 g·mol−13d model (jsmol)interactive image smiles coc1=cc2=cc=c(c=c2c=c1)c(c)c(=o)oc3=cc=c(c=c3)c(n)=s inchi inchi=1s/c21h19no3s/c1-13(21(23)25-18-8-5-14(6-9-18)20(22)26)15-3-4-17-12-19(24-2)10-7-16(17)11-15/h3-13h,1-2h3,(h2,22,26)/t13-/m0/s1key:ycnmaplpqyqjfc-zdusscgksa-n other in vivo studies have demonstrated a reduction in zymosan-induced pain and inflammation and cytokine-induced bone loss. preclinical studies have also investigated the treatment of melanoma, intestinal cancer, and periodontitis. pharmacology further information: nsaid § mechanism of action like other nsaids, otenaproxesul acts as an inhibitor of the cycloxygenase (cox) enzymes, suppressing the production of prostaglandins. additionally, it releases hydrogen sulfide in the gastrointestinal tract, reducing gastrointestinal adverse effects such as ulcers.